Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
Lai Wei(Tongji University), Zhongping Duan(Capital Medical University), Anu Osinusi(Gilead Sciences (United States)), Jidong Jia(National Clinical Research Center for Digestive Diseases), Hong Tang(Sichuan University), Grégory Camus(Gilead Sciences (United States)), Zhuangbo Mou(Jinan Infectious Disease Hospital), Brian McNabb(Gilead Sciences (United States)), Peng Hu(Chongqing Medical University), Lunli Zhang(Nanchang University), Fangqiu Zhang(Gilead Sciences (United States)), Yanhang Gao(Jilin University), Qing Xie(Ruijin Hospital), Jin Hou(Nanfang Hospital), Yuemin Nan(Hebei Medical University), Jun Li(Xuzhou Medical College), Jun Cheng(Central South University), Qin Ning(Huazhong University of Science and Technology), Guiqiang Wang(Qinghai University), Diana M. Brainard(Gilead Sciences (United States)), Shanming Wu(Shanghai Public Health Clinical Center), Hongmei Mo(Gilead Sciences (United States)), Guozhong Gong(Central South University), Jianning Jiang(Guangxi Medical University)
Cited by 22
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
|New England Journal of Medicine|2017|565
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
|New England Journal of Medicine|2022|312